STAT | Reporting from the frontiers of health and medicine 中文 关注 STAT+：Pharmalittle：我们读到 Eyepoint 遭遇挫折，Amylyx 取得胜利，以及更多内容” Eyepoint 披露，其针对年龄相关性失明常见病因的实验性治疗的 III 期临床试验未达到主要目标。 STAT+: Pharmalittle: We’re reading about a setback for Eyepoint, a win for Amylyx, and more statnews.com STAT | Reporting from the frontiers of health and medicine 中文 RSS thenote.app
